on November 3, 2005
Published online before print November 3, 2005, doi: 10.1161/01.ATV.0000194099.65024.17
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 12, 2005
Accepted on October 14, 2005
Interleukin 6 -174 G/C Promoter Polymorphism and Risk of Coronary Heart Disease. Results from the Rotterdam Study and a Meta-Analysis
M. P.S. Sie ;
From the Departments of Epidemiology and Biostatistics (M.P.S.S., F.A.S-T., H.H.S.O., A.G.U., H.A.P.P., A.H., C.M.v.D., J.C.M.W.) and Internal Medicine (M.P.S.S., A.G.U., H.A.P.P.), Erasmus Medical Center, Rotterdam, the Netherlands.
* To whom correspondence should be addressed. E-mail: j.witteman{at}erasmusmc.nl.
Objective--Inflammation plays a pivotal role in the pathogenesis of atherosclerosis. Interleukin (IL) 6 has many inflammatory functions, and the IL-6 -174 G/C promoter polymorphism appears to influence IL-6 levels. Findings of previous studies on the relation between this polymorphism and risk of cardiovascular diseases are inconsistent. We investigated this polymorphism in relation to risk of coronary heart disease (CHD) in a population-based study and meta-analysis.
Methods and Results--Participants (6434) of the Rotterdam Study were genotyped. Analyses on the relation between genotype and CHD were performed using Cox proportional hazards tests, and the association between genotype and plasma levels of IL-6 and C-reactive protein was investigated. All of the analyses were adjusted for age, sex, and common cardiovascular risk factors. A meta-analysis was performed, using a random effects model. No association between genotype and risk of CHD was observed. The polymorphism was not associated with IL-6 levels, but the C-allele was associated with higher C-reactive protein levels (P<0.01). Our meta-analysis did not show a significant association between the genotype and risk of CHD.
Conclusions--We conclude that the polymorphism is not a suitable genetic marker for increased risk of CHD in subjects 
55 years of age.
Key words: coronary heart disease • inflammation • IL-6 • polymorphism
This article has been cited by other articles:
 |
|
 |
|
  D. Corella, J. I. Gonzalez, M. Bullo, P. Carrasco, O. Portoles, J. Diez-Espino, M. I. Covas, V. Ruiz-Gutierrez, E. Gomez-Gracia, F. Aros, et al. Polymorphisms Cyclooxygenase-2 -765G>C and Interleukin-6 -174G>C Are Associated with Serum Inflammation Markers in a High Cardiovascular Risk Population and Do Not Modify the Response to a Mediterranean Diet Supplemented with Virgin Olive Oil or Nuts J. Nutr., January 1, 2009; 139(1): 128 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Priori, C. Napolitano, S. E. Humphries, and J. Skipworth CHAPTER 9 Genetics of Cardiovascular Diseases ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Fleming and G. M. Harrington What Is the Relationship Between Myocardial Perfusion Imaging and Coronary Artery Disease Risk Factors and Markers of Inflammation? Angiology, March 1, 2008; 59(1): 16 - 25. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Qi, C. Zhang, R. M. van Dam, and F. B. Hu Interleukin-6 Genetic Variability and Adiposity: Associations in Two Prospective Cohorts and Systematic Review in 26,944 Individuals J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3618 - 3625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Ntzani, E. C. Rizos, and J. P. A. Ioannidis Genetic Effects versus Bias for Candidate Polymorphisms in Myocardial Infarction: Case Study and Overview of Large-Scale Evidence Am. J. Epidemiol., May 1, 2007; 165(9): 973 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P.S. Sie, A. G. Uitterlinden, M. J. Bos, P. P. Arp, M. M.B Breteler, P. J. Koudstaal, H. A.P. Pols, A. Hofman, C. M. van Duijn, and J. C.M. Witteman TGF-{beta}1 Polymorphisms and Risk of Myocardial Infarction and Stroke: The Rotterdam Study Stroke, November 1, 2006; 37(11): 2667 - 2671. [Abstract] [Full Text] [PDF]
|
|